Overview

Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction

Status:
Not yet recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

The study aims to evaluate whether an early intracoronary administration of Fasudil Hydrochloride during primary PCI of STEMI can improve epicardial and myocardial perfusion as well as clinical outcomes.

Phase:

Phase 4

Details

Lead Sponsor:

RenJi Hospital

Treatments:

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
Fasudil
Glucuronyl glucosamine glycan sulfate